Skip to main content

Advertisement

Log in

Exploring the therapeutic efficacy of crocetin in oncology: an evidence-based review

  • Review
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

With cancer being a leading cause of death globally, there is an urgent need to improve therapeutic strategies and identify effective chemotherapeutics. This study aims to highlight the potential of crocetin, a natural product derived from certain plants, as an anticancer agent. It was  conducted an extensive review of the existing literature to gather and analyze the most recent data on the chemical properties of crocetin and its observed effects in various in vitro and in vivo studies. The study  particularly focused on studies that examined crocetin’s impact on cell cycle dynamics, apoptosis, caspases and antioxidant enzyme levels, tumor angiogenesis, inflammation, and overall tumor growth. Crocetin exhibited diverse anti-tumorigenic activities including inhibition of tumor cell proliferation, apoptosis induction, angiogenesis suppression, and potentiation of chemotherapy. Multiple cellular and molecular pathways such as the PI3K/Akt, MAPK and NF-κB were modulated by it. Crocetin demonstrates promising anti-cancer properties and offers potential as an adjunctive or alternative therapy in oncology. More large-scale, rigorously designed clinical trials are needed to establish therapeutic protocols and ascertain the comprehensive benefits and safety profile of crocetin in diverse cancer types.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

ALDH:

aldehyde dehydrogenase

ATG1:

AuTophaGy-related 1

ATPase:

Adenosine 5′-TriPhosphatase

Bax:

Bcl-2-associated X protein

Bcl2:

B-cell CLL/lymphoma 2

CAT:

catalase

CCD:

carotenoid-cleaving dioxygenase

CDC:

cell division cycle

COX-2:

Cyclooxygenase-2

CXCR4:

C-X-C motif chemokine receptor 4

Cyt. C:

Cytochrome c

EGFR:

epidermal growth factor receptor

ERK1/2:

extracellular signal-regulated protein kinase

GABA:

gamma-aminobutyric acid

GPx:

glutathione peroxidase

GST:

Glutathione S-transferase

HDAC:

histone deacetylase

HMGB1:

High mobility group box 1

I/R:

ischemia-reperfusion

IL:

interleukine

LDH:

lactate dehydrogenase

LDL:

low density lipoproteins

MIA-PaCa-2 cells:

human pancreatic cancer cell line

MMP:

matrix metalloproteinase

MRP:

multidrug resistance-associated protein

MT-MMP:

membrane-type matrix metalloproteinase

NA:

Norepinephrinum

NF-кB:

nuclear factor kappa-light-chain-enhancer of activated B cells

NO:

nitric oxide

OCT3/4:

octamer binding transcription factor 3/4

PCNA:

proliferating cell nuclear antigen

PG-2:

Prostaglandin-2

PI3K:

phosphatidylinositol 3-kinase

PML:

Promyelocytic leukemia protein

PML/RARα:

promyelocytic leukemia/retinoic acid receptor-α

PTH2:

Patched 2

RARα:

retinoic acid receptor α

RNA:

ribonucleic acid

Rohament CL:

liquid formulated fungal cellulase enzyme for hydrolysing non-starch polysaccharides

ROhmenzym:

Cellulytic Enzyme Mixture EL1-77, batchEL2012083, AB-Enzymes, Darmstadt, Germany

ROS:

radical oxygen species

SCFE:

supercritical fluid extraction

SHH:

sonic hedgehog protein

SOD:

superoxide dismutase

TDP1:

tyrosyl-DNA phosphodiesterase 1

TNF:

tumor necrosis factor

TUNEL:

terminal deoxynucleotidyl transferase dUTP nick end labeling

VEGF:

vascular endothelial growth factor

References

Download references

Author information

Authors and Affiliations

Authors

Contributions

W.K., A.W., W.K.-K., M.Z., P.H., Z.M.A., B.A.-O., D.C., J.S.-R., made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas that is, revising or critically reviewing the article; giving final approval of the version to be published; agreeing on the journal to which the article has been submitted; and confirming to be accountable for all aspects of the work. All authors have read and agreed to the published version of the manuscript. The authors confirm that no paper mill and artificial intelligence was used.

Corresponding authors

Correspondence to Daniela Calina or Javad Sharifi-Rad.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koch, W., Wawruszak, A., Kukula-Koch, W. et al. Exploring the therapeutic efficacy of crocetin in oncology: an evidence-based review. Naunyn-Schmiedeberg's Arch Pharmacol 397, 1455–1476 (2024). https://doi.org/10.1007/s00210-023-02714-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-023-02714-z

Keywords

Navigation